The Phase 2 REFINE Trial: Ruxolitinib Plus Navitoclax for Myelofibrosis

Naveen Pemmaraju, MD, provides his expert perspective on currently available treatment options in myelofibrosis and data from the REFINE trial on the experimental therapy of ruxolitinib plus navitoclax.

EP. 1: An Overview of Myelofibrosis

April 19th 2022

Naveen Pemmaraju, MD, provides an overview of myelofibrosis, including a comparison of primary and secondary myelofibrosis and the risk stratification.

EP. 2: The Role of Biomarker Testing in Patients with Myelofibrosis

April 19th 2022

Dr Naveen Pemmaraju explains the relationship of the JAK/STAT pathway to myelofibrosis and the molecular mutations he looks for with biomarker testing.

EP. 3: Current Treatment Options in Myelofibrosis

April 19th 2022

Naveen Pemmaraju, MD, describes the currently available treatment options for patients with myelofibrosis.

EP. 4: Study Design and Outcomes of the Phase II REFINE Trial

April 19th 2022

A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.

EP. 5: Potential Implications of the REFINE Trial on the Myelofibrosis Treatment Paradigm

April 19th 2022

Naveen Pemmaraju, MD, talks about the potential implications of the phase II REFINE trial on the myelofibrosis treatment paradigm.

EP. 6: Investigational Agents and Unmet Needs in Myelofibrosis Treatment

April 19th 2022

Dr Naveen Pemmaraju discusses exciting potential treatment options in myelofibrosis and some unmet needs and ongoing challenges in the treatment landscape.